This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-28. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
=== Origins === Modern dentistry in Chengdu developed in the early 20th century through the work of Western medical missionaries. Ashley Woodward Lindsay, a graduate of the Royal College of Dental Surgeons of Ontario in Toronto, left Canada for Chengdu in 1907. With assistance from physician and missionary Omar L. Kilborn, Lindsay established a dental clinic on Sishengci Street. A history published through China's National Health Commission describes the clinic as marking the beginning of modern dentistry in Chengdu. Sichuan University dates the institutional history of the present hospital to the establishment of the Renji Dental Clinic in 1907. It records the expansion of the clinic into the Renji Dental Hospital in 1912. The hospital describes the 1912 institution as China's first specialized dental hospital. West China Union University, a missionary-founded university established in Chengdu in 1910, subsequently became the principal institutional base for Lindsay's dental work. In 1917, the university established its dental education program. The dental school at West China Union University was the earliest dental education institution in China. Several early faculty members were trained at the University of Toronto Faculty of Dentistry, which credits these dentists with helping introduce a university-based model of dental education to China and with contributing to the development of national dental-education standards. In the late 1920s the medical and dental programs of West China Union University were brought into a combined academic structure.
== P == Paal–Knorr pyrrole synthesis Paal–Knorr synthesis Paneth technique Passerini reaction Paternò–Büchi reaction Pauson–Khand reaction Payne rearrangement Pechmann condensation Pechmann pyrazole synthesis Pellizzari reaction Pelouze synthesis Peptide synthesis Perkin alicyclic synthesis Perkin reaction Perkin rearrangement Perkow reaction Petasis reaction Petasis reagent Peterson olefination Peterson reaction Petrenko-Kritschenko piperidone synthesis Pfau–Plattner azulene synthesis Pfitzinger reaction Pfitzner–Moffatt oxidation Phosphonium coupling Photosynthesis Piancatelli rearrangement Pictet–Gams isoquinoline synthesis Pictet–Hubert reaction Pictet–Spengler tetrahydroisoquinoline synthesis Pictet–Spengler reaction Piloty–Robinson pyrrole synthesis Pinacol coupling reaction Pinacol rearrangement Pinner amidine synthesis Pinner method for ortho esters Pinner reaction Pinner triazine synthesis Pinnick oxidation Piria reaction Polonovski reaction Pomeranz–Fritsch reaction Ponzio reaction Prato reaction Prelog strain Prevost reaction Prileschajew reaction Prilezhaev reaction Prins reaction Prinzbach synthesis Protecting group Pschorr reaction Pummerer rearrangement Purdie methylation, Irvine–Purdie methylation
Alcohol: It has been reported that combined use of alcohol and kava extract can have additive sedative effects. Kava has been shown to create additive cognitive impairments when taken with alcohol, compared to taking placebo and alcohol alone. Anxiolytics (CNS depressants such as benzodiazepines and barbiturates): Kava may have potential additive CNS depressant effects (such as sedation and anxiolytic effects) with benzodiazepines and barbiturates. Kava taken in combination with alprazolam can cause a semicomatose state in humans. Dopamine agonist such as levodopa: One of levodopa's chronic side effects in Parkinson's patients is the "on-off phenomenon" of motor fluctuations - periods of oscillations between "on", where the patient experiences symptomatic relief, and "off", where the therapeutic effect wears off early. When levodopa and kava are taken together, it has been shown that there is an increased frequency of this "on-off phenomenon".
Sources: en.wikipedia.org
== Mechanisms == LEDs are the most utilized optical semiconductor devices that transform electrical energy into light energy. LED therapy utilizes light-emitting diodes to deliver treatments based on mechanisms such as photodynamic Therapy (PDT) and photobiomodulation (PBMT). PDT targets and destroys diseased cells, while PBMT stimulates cellular repair and reduces inflammation. The effectiveness of LED therapy varies with the wavelength of light, allowing for diverse applications in healing, dermatology, and cancer treatment.
. The simulation first updates the infected from the susceptible and then the removed category is updated from the infected category for the next time point (t=1). This describes the flow persons between the three categories. During an epidemic the susceptible category is not shifted with this model,
== Epidemiology == Studies have found the prevalence of heightened IGF-1 levels in cats with diabetes mellitus to range between 17.8% and 27.3%. According to Claudia Reusch, a professor at the University of Zurich, the prevalence of hypersomatotropism in diabetic cats is 10–15%, in cases that are hard to regulate it rises to 30% or higher.
Acetaldehyde (ethereal) Hexanal (green, grassy) cis-3-Hexenal (green tomatoes) Furfural (burnt oats) Hexyl cinnamaldehyde Isovaleraldehyde – nutty, fruity, cocoa-like Anisic aldehyde – floral, sweet, hawthorn. It is a crucial component of chocolate, vanilla, strawberry, raspberry, apricot, and others. Cuminaldehyde – Spicy, cumin-like, green
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.